TRP_1170x120_12-19-19

Johnson & Johnson

Johnson & Johnson announces CFO succession

Johnson & Johnson announces CFO succession

NEW BRUNSWICK, N.J. — Dominic Caruso, executive vice president and chief financial officer at Johnson & Johnson, is slated to retire this fall and be succeeded by Joseph Wolk. The company said late Tuesday that Caruso, who plans to retire in September, has served as Johnson & Johnson CFO longer than anyone in its 132- year

Johnson & Johnson to buy Actelion for $30 billion

Johnson & Johnson to buy Actelion for $30 billion

NEW BRUNSWICK, N.J. — Johnson & Johnson has reached an agreement to acquire Switzerland-based biopharmaceutical company Actelion Ltd. for $30 billion in cash. J&J said Actelion’s differentiated, innovative products for pulmonary arterial hypertension (PAH) are highly complementary to the portfolio of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company also noted that the

J&J’s Joaquin Duato tabbed as PhRMA chairman

J&J’s Joaquin Duato tabbed as PhRMA chairman

WASHINGTON — The Pharmaceutical Research and Manufacturers of America has named Joaquin Duato, worldwide chairman of pharmaceuticals as Johnson & Johnson, as chairman of the PhRMA board of directors. Duato previously was chairman-elect on the PhRMA board and succeeds George Scangos, who has stepped down as chief executive officer of Biogen. “In the words of

Survey: Consumers lax in using OTC pain relievers safely

Survey: Consumers lax in using OTC pain relievers safely

FORT WASHINGTON, Pa. — Many consumers don’t heed safety factors when choosing and using over-the-counter pain relievers, a national survey supported by McNeil Consumer Healthcare finds. Of 1,292 U.S. adults who have used an OTC pain reliever in the last 90 days, 65% don’t consider other OTC medicines they are taking and 45% don’t take

GMDC: People with diabetes turning to retailers for help

GMDC: People with diabetes turning to retailers for help

COLORADO SPRINGS, Colo. — As consumers with diabetes take more control over their care, food and pharmacy retailers are being challenged to come up with solutions to meet their needs, according to research from the Global Market Development Center (GMDC). GMDC’s latest Health & Wellness Best Practices report, titled “Retail Partnering to Serve the Shopper

J&J plans diabetes ‘zone’ at Total Store Expo

J&J plans diabetes ‘zone’ at Total Store Expo

NEW BRUNSWICK, N.J. — Health care giant Johnson & Johnson is sharpening its aim at the growing diabetes epidemic. J&J said this week that it plans to debut the Diabetes Collaboration Zone, a cross-enterprise display of diabetes-focused products, solutions and resources, at the 2016 National Association of Chain Drug Stores Total Store Expo, which runs

Mylanta heartburn remedy returns to stores

Mylanta heartburn remedy returns to stores

WESTPORT, Conn. — The venerable Mylanta antacid and anti-gas liquid has been brought back to store shelves nationwide by Infirst Healthcare USA, a subsidiary of United Kingdom-based Infirst Healthcare Ltd. Infirst said Tuesday that the “new” Mylanta features an improved taste, extra coating power and new products. The original product, made by Johnson & Johnson’s

J&J to buy Vogue International for $3.3 billion

J&J to buy Vogue International for $3.3 billion

NEW BRUNSWICK, N.J. — Johnson & Johnson Consumer Inc. plans to acquire Vogue International, maker of the OGX hair care brand, for about $3.3 billion in cash. Johnson & Johnson said Thursday that the deal includes the OGX line of shampoos, conditioners, treatments, styling products, body care and bath products, as well as the FX

Cardinal Health closes Cordis acquisition

Cardinal Health closes Cordis acquisition

DUBLIN, Ohio — Cardinal Health has completed its acquisition of Johnson & Johnson’s Cordis cardiology and endovascular device business for $1.944 billion. Cardinal said Sunday evening that the integration of Cordis off to a strong start, with management teams in place worldwide. The company noted that planning has been ongoing since the deal was announced

J&J, P&G collaborations target flu, heart disease

J&J, P&G collaborations target flu, heart disease

Two major drug chain manufacturer partners — Johnson & Johnson and Procter & Gamble — are involved in collaborations that could make a big impact in fighting flu and heart disease. Scientists from The Scripps Research Institute (TSRI) and J&J’s Janssen pharmaceutical subsidiary have found a way to induce antibodies to fight a wide range

Walgreens, J&J push healthy choices

NEW BRUNSWICK, N.J. — Johnson & Johnson Consumer Products Inc. (J&J) is now sponsoring the Walgreens Balance Rewards for healthy choices program in order to encourage and reward healthy behavior. Centered on the shared belief that the health and well-being of families everywhere is critically important, both companies are making it easier for customers to

MPG founding partner Toohey to retire

MPG founding partner Toohey to retire

PRINCETON JUNCTION, N.J. — Market Performance Group (MPG) announced that founding partner Tim Toohey is retiring and that the company has named two new members to its advisory board. MPG said Tuesday that Toohey is retiring to pursue other business and personal interests but will continue to contribute his knowledge and consulting expertise as a

Cardinal Health to acquire Cordis from J&J

DUBLIN, Ohio — Cardinal Health Inc. plans to acquire cardiology and endovascular device maker Cordis from Johnson & Johnson for $1.944 billion. Cardinal said Monday that the cash deal would significantly advance its offering of interventional cardiology and endovascular solutions for integrated health systems and their patients by giving the company immediate global scale in